Results 71 to 80 of about 84,926 (204)

An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial [PDF]

, 2016
Background: Cardiovascular diseases (CVD) are responsible for significant morbidity, premature mortality, and economic burden. Despite established evidence that supports the use of preventive medications among patients at high CVD risk, treatment gaps ...
Adina Hayek, Anthony Rodgers, Antithrombotic Trialists’ Collaboration, Antithrombotic Trialists’ Collaboration, Anushka Patel, B Mitchell, B Patel, Baldeep Kaur, Bandana Saini, BL Carter, BL Svarstad, BL Svarstad, Blood Pressure Lowering Treatment Trialists' Collaboration, C Armour, C Baigent, Carol Armour, Charlotte Hespe, Christopher Reid, D Peiris, D Peiris, D Peiris, David Peiris, DE Morisky, DE Morisky, DM Wentzlaff, DP Peiris, E Hatah, EL Heeley, Fred Hersch, GF Moore, Ines Krass, JK Lee, KL Margolis, Louise Shiel, M Krousel-Wood, MP Morgado, N Houston Miller, P Ho, R Webster, RB Haynes, RJ Webster, Rohina Joshi, Ruth Webster, S Jan, S Michie, Serigne Lo, Stephen Jan, Tim Usherwood, Tracey-Lea Laba, WK Kellogg Foundation, World Health Organisation   +50 more
core   +4 more sources

Pharmacological effects of raas blockade in ischemic nephropathy [PDF]

, 2016
Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio, Cianci, Rosario, Coppolino, Giuseppe, Di Mario, Francesca, Farrah, Tariq E., Fuiano, Giorgio, Gigante, Antonietta, Rivoli, Laura, Rosato, Edoardo   +8 more
core   +1 more source

Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]

, 2018
© The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez, C Varenhorst, D Alexopoulos, D Aradi, D Lindholm, D Zhou, EA Amsterdam, F Franchi, G Parodi, G Parodi, H Sillén, HS Smith, J Kubica, J Kubica, J Li, JH Cornel, JM Siller-Matula, K Butler, K Butler, K Thygesen, M Koziński, M Roffi, P Adamski, P Adamski, P Adamski, P Adamski, P Niezgoda, P Niezgoda, PG Steg, PG Steg, PT O’Gara, R Teng, R Teng, R Teng, R Teng, R Teng, R Teng, RA Lange, S Husted, S James, SE Husted, SS Brar   +41 more
core   +2 more sources

S-Nitrosoglutathione reduces asymptomatic embolization after carotid angioplasty [PDF]

, 2002
Background: The major complication of carotid angioplasty is embolic stroke, which may occur after balloon inflation and deflation or in the early postintervention period.
Clifton, A., Kaposzta, Z., Markus, H.S., Martin, J.F., Molloy, J.   +4 more
core   +1 more source

A-19 | Abbreviated Versus Prolonged Dual Antiplatelet Therapy (DAPT) Following Percutaneous Coronary Intervention (PCI) with Drug-Eluting Stents (DES): A Meta-Analysis of Randomized Controlled Trials (RCTs) [PDF]

, 2022
Abdulbaril Olagunju, Jumanah Abuasbeh, Ayman R. Fath, Ali Moradi, Ross Johnson, Zachary Lebaron, Mehrdad Saririan   +6 more
openalex   +1 more source

ANTIPLATELET THERAPY IN PROPHILAXY OF NEGATIVE CARDIOVASCULAR EVENTS AFTER CORONARY REVASCULARIZATION. IS THERE A CONSENSUS?

Российский кардиологический журнал, 2014
The review provides the current information about the role of antiplatelet therapy in the cardiovascular prevention in patients with coronary artery disease and coronary revascularization.
Yu. I. Grinschtein, A. A. Kosinova, I. Yu. Grinschtein   +2 more
doaj   +1 more source

Serotonin reuptake inhibitors and cardiovascular disease [PDF]

, 2005
Selective serotonin re-uptake inhibiting drugs (SSRIs) are widely used for endogenous depression. In addition to depleting the nerve terminals of serotonin they also lower blood platelet serotonin levels.
Belcher, P.R., Drake-Holland, A.J., Noble, M.   +2 more
core   +1 more source

One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke [PDF]

, 2016
BACKGROUND Previous studies conducted between 1997 and 2003 estimated that the risk of stroke or an acute coronary syndrome was 12 to 20% during the first 3 months after a transient ischemic attack (TIA) or minor stroke.
Albers, Gregory W., Amarenco, Pierre, Bornstein, Natan M., Canhão, Patrícia, Caplan, Louis R., Donnan, Geoffrey A., Ferro, José M., Hennerici, Michael G., Labreuche, Julien, Lavallée, Philippa C., Molina, Carlos, org Steering Committee, T. I. A. r. e. g. i. s. t. r. y., Rothwell, Peter M., Sissani, Leila, Steg, Philippe Gabriel, Toni, Danilo, Touboul, Pierre Jean, Uchiyama, Shinichiro, Vicaut, Éric, Wong, Lawrence K. S., Školoudík, David   +20 more
core   +2 more sources

Antiplatelet and anticoagulant therapy in elderly people with type 2 diabetes mellitus in Poland (based on the PolSenior Study)

Archives of Medical Science, 2017
Introduction: Type 2 diabetes mellitus (T2DM) is an important and common cardiovascular risk factor. The purpose of the study was to evaluate the frequency of use of oral antiplatelet drugs (OAPs) and oral anticoagulant drugs (OACs) among the elderly ...
Beata Łabuz-Roszak, Agnieszka Machowska-Majchrzak, Michał Skrzypek, Małgorzata Mossakowska, Jerzy Chudek, Andrzej Więcek, Maciej Wawrzyńczyk, Beata Łącka-Gaździk, Krystyna Pierzchała   +8 more
doaj   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources